Varex Imaging Corporation
VREXHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeVarex Imaging Corporation designs, manufactures, and sells X-ray imaging components. With a market capitalization of $779.3M, it sits in small-cap territory. It operates through two segments, Medical and Industrial.
Market Cap
$779.3M
Beta
0.96
P/E (TTM)
34.89
P/E (Fwd)
17.28
EPS (TTM)
$0.53
EPS (Fwd)
$1.07
ROE
4.6%
ROA
4.2%
Cash
$100.1M
Total Debt
$379.3M
Free CF
-$39.5M
52W Change
68.9%
Annual Financials
Cash vs Debt
Where VREX stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, VREX finished 51.68% above its 150-day moving average ($12.19) and 51.68% above its 200-day moving average ($12.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VREX overbought or oversold?
At the September 1, 2026 close, VREX's RSI(14) was 37.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Varex Imaging Corporation carries $379.3M in total debt against $100.1M in cash reserves — debt is roughly 3.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$39.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 4.6% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.2% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $859.4M (2022) to $844.6M (2025).
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VREX.